LSR Stock Chart & Stats
€1.00
€0.00(0.00%)
At close: 4:00 PM EDT
€1.00
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.76 - €9.70
Previous CloseN/A
Volume0.00
Average Volume (3M)63.00
Market Cap
€23.55M
Enterprise Value€13.97
Total Cash (Recent Filing)€6.53M
Total Debt (Recent Filing)€7.89M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
Dec 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.58
Shares Outstanding17,588,987
10 Day Avg. Volume90
30 Day Avg. Volume63
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.34
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.64
Revenue Forecast (FY)€4.11M
Bulls Say, Bears Say
Bulls Say
Biomarker-selected Multikine StrategyA biomarker-guided trial design could improve patient selection and strengthen the probability of demonstrating a reproducible survival benefit, potentially supporting regulatory approval and future commercialization if the confirmatory study succeeds.
Clinical Efficacy SignalThe reported long-term survival difference provides a meaningful clinical rationale for continued development and may help differentiate Multikine in head and neck cancer, although the benefit still requires confirmation in the registration study.
Potential Commercial Pathway And CDMO DiversificationThe Amarox relationship could establish an initial regional commercialization route, while CDMO capabilities offer a non-product service model. Together, they provide potential diversification beyond dependence on Multikine approval alone.
Bears Say
No Demonstrated Commercial RevenueZero reported revenue confirms that Cel-Sci remains pre-commercial and has not yet demonstrated product-market adoption or scalable sales. The company therefore remains dependent on clinical success, financing, partnerships, or CDMO demand.
Persistent Cash BurnConsistently negative operating and free cash flow means the business is not self-funding. Continued clinical development and commercialization preparation will likely require additional capital, creating dilution or financing risk.
Balance-sheet Volatility And Capital EfficiencyThe sharp reported change in debt and asset scale creates substantial uncertainty about balance-sheet quality and future obligations. Deeply negative returns on equity also indicate that invested capital has not generated economic returns.
Cel-Sci News
LSR FAQ
What was Cel-Sci Corp.’s price range in the past 12 months?
Cel-Sci Corp. lowest stock price was €0.76 and its highest was €9.70 in the past 12 months.
What is Cel-Sci Corp.’s market cap?
Cel-Sci Corp.’s market cap is €23.55M.
When is Cel-Sci Corp.’s upcoming earnings report date?
Cel-Sci Corp.’s upcoming earnings report date is Dec 23, 2026 which is in 126 days.
How were Cel-Sci Corp.’s earnings last quarter?
Cel-Sci Corp. released its earnings results on Aug 17, 2026. The company reported -€0.406 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Cel-Sci Corp. overvalued?
According to Wall Street analysts Cel-Sci Corp.’s price is currently Overvalued.
Does Cel-Sci Corp. pay dividends?
Cel-Sci Corp. does not currently pay dividends.
What is Cel-Sci Corp.’s EPS estimate?
Cel-Sci Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cel-Sci Corp. have?
Cel-Sci Corp. has 17,588,987 shares outstanding.
What happened to Cel-Sci Corp.’s price movement after its last earnings report?
Cel-Sci Corp. reported an EPS of -€0.406 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cel-Sci Corp.?
Currently, no hedge funds are holding shares in DE:LSR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cel-Sci Corp.
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.